Unichem Laboratories Gets ANDA Approval for Prasugrel Tablets

Last edition

Unichem Laboratories Gets ANDA Approval for Prasugrel Tablets

Unichem Laboratories Ltd. has received ANDA approval for its Prasugrel Tablets USP, 5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Effient® (Prasugrel) Tablets, 5 mg and 10 mg, of Cosette Pharmaceuticals, Inc.

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome. The product will be commercialized from Unichem's Goa Plant.

Read more on:
Unichem Laboratories

More news about: global pharma | Published by Manvi | August - 31 - 2023 | 296

Last news about this category

DOSIsoft Unveils PLANET Onco Dose v3.2 with EU MDR and FDA 510(k) Clearance

Zydus Lifesciences' VC Arm Invests in Canada's Feldan Therapeutics to Advance Intracellular Drug Delivery

Medline UNITE Earns FDA 510(k) Clearance for REFLEX HYBRID Nitinol Implant System

ScreenPoint Medical to Showcase New Transpara Breast AI Features at 2025 SBI Symposium

Steriline to Debut at Pharmintech 2025 with Innovative Filling and Capping Machine

Chime Biologics, Polpharma Biologics Join Hands to Advance Global Biosimilar Development

Nikon CeLL Innovation Enters into Strategic Licensing Agreement with RoosterBio

Terumo Neuro Secures FDA Premarket Approval for Carotid Stent System

LUMA Vision Launches VERAFEYE, the First-of-Its-Kind Platform for Advanced Intracardiac Visualisation

First-in-Human Trial of VAS-101 Topical Curcumin Gel for Sickle Cell Disease Begins in Florida

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy